tbuckley/cabot-search huggingface dataset:
A Spotlight on Sunscreen Regulation
Authors: Joshua M. Sharfstein
Journal: New England Journal of Medicine (2015)

Interview with Dr. Joshua Sharfstein on the process of approving new sunscreen ingredients for marketing in the United States. (08:37)Download In recent months, the FDA has declined to permit use of eight new sunscreen ingredients (that are already in use in Europe) without additional data. The controversy says as much about how the agency works as it does about sunscreen regulation.
Abstract 4661: Impact of Alerts on Outcome of the Fidelis Implantable Cardioverter-Defibrillator Lead Advisory: A Report from the Canadian Heart Rhythm Society Device Advisories Committee
Authors: Andrew D Krahn, David H Birnie, Jean Champagne, Jeffrey S Healey, Doug Cameron, Christopher S Simpson, Bernard Thibault, Iqwal Mangat, Stanley Tung, Laurence Sterns, Derek Exner, Ratika Parkash, Soori Sivakumaran, Ted Davies, Benoit Coutu, Eugene Crystal, Kevin Wolfe, Atul Verma, Elizabeth A Stephenson, Shubhayan Sanatani, Robert Gow, Sean Connors, Felix Ayala-Paredes, Vidal Essebag
Journal: Circulation (2008)
Abstract P2-05-13: Transcriptomic profiling of patient sequential tumours provides cutting edge view of global metastatic expression changes following endocrine therapy
Authors: Jean McBryan, Ailis Fagan, Damian McCartan, Jarlath C Bolger, Fiona T Bane, Christopher Byrne, Marie McIlroy, Arnold D Hill, Leonie S Young
Journal: Cancer Research (2015)

Abstract Disease recurrence is a common problem in breast cancer and yet the mechanisms enabling tumour cells to evade therapy and colonise distant organs remain unclear. Here, for the first time, RNAsequencing has been performed on matched primary, nodal and liver metastatic tumours from three tamoxifen-treated patients following metastatic disease progression. Despite all primary tumours being of a luminal subtype and all cancers metastasising to the liver, the extent of patient heterogeneity at the gene level was striking. Less than 3% of the genes differentially expressed between sequential tumours were common to all patients. Larger divergence was observed between primary and liver tumours than between primary and nodal tumours, reflecting both the latency time to disease progression and the genetic impact of endocrine therapy. Furthermore, a xenograft model demonstrated the ability of tamoxifen to drive disease progression and establish distant metastatic disease in the endocrine resistant setting. Common functional pathways altered during metastatic, endocrine-resistant progression included ECM receptor interactions and focal adhesions. This novel global analysis highlights the influence of primary tumour biology in determining the transcriptomic profile of metastatic tumours, as well as the need for adaptations in cell-cell communications in order for tumour cells to successfully colonise distant host organs. Citation Format: Jean McBryan, Ailis Fagan, Damian McCartan, Jarlath C Bolger, Fiona T Bane, Christopher Byrne, Marie McIlroy, Arnold D Hill, Leonie S Young. Transcriptomic profiling of patient sequential tumours provides cutting edge view of global metastatic expression changes following endocrine therapy [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-05-13.
Abstract 13983: Long-term Device-Related Adverse Events After Cardiac Resynchronization Therapy: Insights From the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT)
Authors: Mario Talajic, Elizabeth Yetisir, L B Mitchell, Marilynn Luce, Patricia Theoret-Patrick, George A Wells, Anthony S Tang
Journal: Circulation (2011)

Cardiac resynchronization therapy (CRT) has been shown to reduce heart failure hospitalization and mortality in patients with congestive heart failure, low ejection fraction and a wide QRS interval...
Immune Profiling To Predict Treatment Response From Extracorporeal Photopheresis In Graft-Versus-Host Disease
Authors: Stefan F Cordes, Michael Gustafson, Douglas Padley, Adam S. Armstrong, Greg Butler, Mrinal M. Patnaik, William Hogan, Mark R. Litzow, Jeffrey L. Winters, Dennis A. Gastineau, Allan B Dietz, Yi Lin, MDPhD, Eapen K. Jacob
Journal: Blood (2013)
Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor
Authors: G. Michael Felker, Javed Butler, Sean P. Collins, Gad Cotter, Beth A. Davison, Justin A. Ezekowitz, Gerasimos Filippatos, Phillip D. Levy, Marco Metra, Piotr Ponikowski, David G. Soergel, John R. Teerlink, Jonathan D. Violin, Adriaan A. Voors, Peter S. Pang
Journal: JACC Heart Failure (2015)
Effect of deprivation on general practitioners' referral rates
Authors: T. Williams, A. Jackson, D. Turbitt, G. Scrivener, D. Lloyd, P. Sturdy, F. Pereira, S. Hull, Y. Carter, J. Naish, C. Harvey, J. Hippisley-Cox, C. Hardy, M. Pringle, R. Carlisle, K. Fielding, C. Chilvers
Journal: BMJ (1997)
Abstract 8680: Long Term Outcomes in Patients with Borderline Prolonged QRS Durations Following Cardiac Resynchronization Therapy
Authors: John Rickard, Jay Sengupta, David O Martin, WH W Tang, Patrick J Tchou, Mina K Chung, Bruce D Lindsay, Bruce L Wilkoff
Journal: Circulation (2011)

Background: The majority of patients enrolled in clinical trials of cardiac resynchronization therapy (CRT) have had significant QRS prolongation with some studies excluding patients with a QRS duration ≤130ms. Current ACC/AHA/HRS guidelines suggest CRT is appropriate for patients with significant LV dysfunction and a QRS duration ≥120ms. Long-term outcomes in patients with only mildly prolonged QRS durations following CRT have not been evaluated. Methods: We collected clinical and electrocardiographic data on a cohort of 895 patients who presented for the initiation of CRT at our institution between 10/29/2003 and 8/6/2007. For inclusion in the final cohort, patients had a valid US social security number, NYHA class II-IV heart failure, a QRS duration ≥ 120 ms, and an LVEF≤40%. Patients with mild baseline QRS prolongation (QRS duration 120-130ms) were compared to patients with more significant QRS prolongation (QRS&gt;130ms) in terms of all-cause mortality. Results: 694 patients met inclusion criteria of which 65 met criteria for a mildly prolonged QRS duration. Over a mean follow up of 4.3±2.0 years, there were 273 deaths, 35 in the mildly prolonged group (53.8%) vs. 238 in patients with significant QRS prolongation (27.8%)(p=0.016). In Cox multivariate regression analysis, patients with mild QRS prolongation had significantly worse long term outcomes compared to those with more significant prolongation(hazard ratio 1.5 (1.02-2.21, p=0.038). Conclusions: Patients with left ventricular dysfunction and only mild QRS prolongation undergoing CRT have increased all-cause mortality compared to more traditionally studied patients with significant QRS widening.
Clinical significance of the interaction between lithium and a neuromuscular blocker
Authors: B A Martin, P M Kramer
Journal: American Journal of Psychiatry (1982)

Reports of delayed recovery from anesthesia by patients concurrently receiving lithium carbonate and a neuromuscular blocker have been followed by a recommendation to avoid such a combination and, hence, concurrent treatment with lithium and electroconvulsive therapy (ECT). The authors review the literature and their clinical experience with such a drug combination at one psychiatric hospital. They conclude that the clinical and experimental findings to date are insufficient to warrant proscribing the combination of lithium and ECT on the basis of possible potentiation of neuromuscular blockade by lithium.
Serum Beta-2 Microglobulin Level As a Useful Prognostic Marker Of Hodgkin Lymphoma
Authors: Yuki Nakajima, Naoto Tomita, Reina Watanabe, Yasufumi Ishiyama, Eri Yamamoto, Daisuke Ishibashi, Megumi Itabashi, Satoshi Koyama, Hiroyuki Takahashi, Ayumi Numata, Hirotaka Takasaki, Rika Kawasaki, Hideyuki Kuwabara, Masatsugu Tanaka, Chizuko Hashimoto, Katsumichi Fujimaki, Rika Sakai, Shigeki Motomura, Yoshiaki Ishigatsubo
Journal: Blood (2013)
Abstract 14981: Prognostic Significance Of Early Repolarization In Inferolateral Leads In Brugada Patients With Documented Ventricular Fibrillation
Authors: Hiro Kawata, Hiroshi Morita, Takashi Noda, Koji Miyamoto, Yuko Yamada, Hideo Okamura, Kazuhiro Satomi, Takeshi Aiba, Naohiko Aihara, Shiro Kamakura, Satoshi Nagase, Kazufumi Nakamura, Kengo Kusano, Hiroshi Ito, Wataru Shimizu
Journal: Circulation (2011)

Background: Prognostic significance of the early repolarization (ER) in inferolateral leads in patients with Brugada syndrome was not known well. The purpose of this study was to investigate the pr...
Going home after a heart attack
Authors: K. Hopcroft
Journal: BMJ (1996)

Table 1-All cause mortality ratios* (95% confidence intervals) adjusted for socioeconomic status among second generation Irish people in England and Wales at working agest during extended period of follow up (1971-92) Women Men Standardised No of Standardised No of mortality ratio deaths mortality ratio deaths Mortality adjusted for: Age 126 (103 to 152)t 104 124 (110 to 140)t 267 Age and social class l-IV § 134 (103 to 170)t 67 129 (111 to 149)t 184 Age, housing tenure, and access to car 126 (102 to 152)t 102 122 (107 to 138)t 247*Relative to all men or all women (standardised mortality ratio = 100).tAges 15-64 for men, 15-59 for women.*Standardised mortality ratio significantly different from 100 at 5% level.§First five years of follow up were excluded to allow for health selection.2
Detection of epidermal growth factor receptor gene mutations in advanced inoperable non-small-cell lung cancer; application of laser capture microdissection to cytologic specimens.
Authors: Yuka Fujita, Yutaka Nishigaki, Mie Aoki, Michiko Shimura, Yasushi Yamamoto, Akinori Takeda, Yasuhiro Yamazaki, Toshiaki Fujikane, Satoru Fujiuchi
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

5656 

Purpose: Recent studies have reported that somatic mutations in the tyrosine kinase (TK) domain of epidermal growth factor (EGFR) gene were associated with clinical response to EGFR tyrosine kinase inhibitor (EGFR-TKI) in non-small lung cancer (NSCLC). These studies analyzed using tissue specimens obtained needle aspirates and surgical resection. Tissue specimens, however, are not available in most patients with advanced inoperable NSCLC at the time of diagnosis and later. The purpose of the present study is to determine the usefulness of EGFR mutations in the cytologic specimens as a predictor for sensitivity to gefitinib. Experimental Design: We examined EGFR mutations in the cytologic specimens in 22 advanced inoperable NSCLC patients treated with gefitinib after prior 1st line chemotherapy or more, and analyzed the relationship between EGFR mutations and clinical features including response to gefitinib. Using Laser Scissors Pro 300 (Cell Robotics Inc), NSCLC cells were selectively microdissected and captured from cytologic specimens. Genomic DNA was extracted from the captured cells. EGFR mutations were detected using PCR-based direct sequencing of the two exons of the TK domain (exon 19 and 21). Results: Genomic DNA was extracted successfully from 22 patients of ethanol-fixed, Papanicolaou stained cytologic specimens. These samples obtained from bronchial brushing (17), bronchial washing (2), sputum (2) and pleural effusion (1). All patients were diagnosed with primary lung adenocarcinomas. One patient had stage IIIB disease and 21 patients had stage IV disease. Thirteen patients achieved a partial response to gefitinib. EGFR mutations were found in 17 of 22 (77.2%) patients with advanced inoperable NSCLC. All mutations were in-flame deletions of codons 746–750 in exon 19 and homozygous. Eleven of the 17 patients with EGFR mutations attained a partial response in contrast with none of the 5 patients with wild-type EGFR (p=0.0110). EGFR mutations were also detected in 11 of 12 never smokers, but the difference was not statistically significant (p=0.0776). There was no correlation between EGFR mutations and gender (p=0.1269). Patients whose tumor with EGFR mutations survived for a longer time than those with wild-type EGFR after gefitinib treatment (p=0.0252, log-rank test). Conclusions: These results suggest that detection of EGFR mutations in cytologic specimens is the useful predictor for gefitinib in the patients with advanced inoperable NSCLC.
Abstract 2665: Cellular Cardiomyoplasty: Optimizing Cellular Dosage and Retention by Microencapsulation
Authors: Adil H AL Kindi, Guang Yong Chen, Juan Francisco Asenjo, Yin Ge, Jasmine Bhathena, Ray C Chiu, Satya Prakash, Dominique Shum-Tim
Journal: Circulation (2007)

Objective: There is no consensus regarding the optimal dose of marrow stromal cells (MSCs) for cellular cardiomyoplasty via direct intramyocardial implantation. Previous studies also demonstrated massive cells loss after injections due to myocardial contraction. Here we studied the dosage at which there is functional improvement, and hypothesized that cellular washout may be reduced by increasing the size of the injectate using microencapsulation. Methods: In Experiment I , 5 groups of rats (n=9/grp) underwent coronary ligation; Grp. I had no treatment; Grp. II to V received escalating 0.5x10 6 , 1.5x10 6 , 3x10 6 and 5x10 6 cells each. Echocardiogram was performed at baseline, 2 days and 6 weeks after surgery to measure ejection fraction ( EF) in a blinded fashion. In Experiment II , fluorescent cell-sized microspheres (10 μm) were encapsulated in Alginate-Poly-l-Lysine-Alginate microcapsules in two different sizes. Each rat received intramyocardial injection of 1x10 6 microspheres. In Grp. A (n=16/grp), rats received bare microspheres, Grp. B, microspheres within 200 μm microcapsules and in Grp. C, microspheres within 400 μm microcapsules were given. After 20 minutes, hearts were harvested and the microspheres retained in the myocardium quantified. Results: In Experiment I , baseline LVEF was 71 ± 1.4%. Two days post MI, EF was 30.5± 10.1% and no statistical difference between groups. EF at 7 weeks was 30± 4.3 in Grp. I, 30.2± 9.4% in Grp. II, 53.8± 11.8% in Grp. III, 54±8.2% in Grp. IV and 52.6 ± 7.5% in Grp. V. The improvement in LVEF was statistically significant between Grps. I-II and Grps. III - V. (p&lt; 0.05, ANOVA and Tukey’s) In Experiment II , the microspheres retention rate was 4.3 ± 3.5% (Grp. A), 16.5 ± 7.7% (Grp. B) and 13±6.3% (Grp. C). The difference between Grp. A vs B and C was statistically significant but not between Grp. B and C . (p&lt; 0.05, ANOVA and Tukey’s) Conclusion: We concluded that functional improvement in this animal model starts at 1.5 x10 6 cells, but is far from optimal. Micoencapsulation increased the retention by 4 folds. Thus this study suggests that improving mechanical retention is possible by microencapsulation of donor stem cells which may facilitate functional improvement of the damaged heart.
Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction
Authors: Lars G. Olsson, Karl Swedberg, Anique Ducharme, Christopher B. Granger, Eric L. Michelson, John J.V. McMurray, Margareta Puu, Salim Yusuf, Marc A. Pfeffer
Journal: Journal of the American College of Cardiology (2006)
Abstract 12066: The Distribution of Epicardial Fat Thickness by Echocardiography among Apparently Healthy Individuals: The ELSA-Brasil Cohort
Authors: Daniela Bertol, Murilo Foppa, Alvaro Vigo, Maria Ines Schmidt, Jose G Mill, Bruce B Duncan
Journal: Circulation (2012)

Introduction: Epicardial fat thickness has emerged as a new marker of cardiometabolic risk. However, previously reported echocardiographic studies are based on convenience samples of patients selec...
Epigenetic regulation, tumorigenesis and drug-induced senescence
Authors: Clare L. Scott, Hans G. Wendel, Masashi Narita, Jesus Gil, David Beach, Scott W. Lowe
Journal: Cancer Research (2004)

4173   Cellular senescence parallels apoptosis as a cellular response to stress and may be important for suppressing tumor development and mediating chemotherapeutic response. We have previously shown that drug-induced senescence is controlled by the p53 and p16 tumor suppressors and may contribute to treatment outcome in vivo1. In vitro, this process involves a global chromatin reorganisation2. To further understand the control of senescence in tumor development and treatment responses, we have taken a multifaceted approach involving the use of genetics and microarray technology to identify factors that influence upstream and downstream elements of the senescence program in vivo. To this end, we have exploited the murine Em-Myc model of B-cell lymphoma, which allows for genetic manipulation i) of hematopoietic stem cells with potential impact on tumorigenesis and/or chemosensitivity and ii) of established lymphoma cells with potential impact on reversal of tumorigenicity and/or chemosensitivity. For example, we have shown that that the novel polycomb protein, CBX7, which epigenetically silences the INK4a/ARF locus, thus inhibiting p16 and p19, dramatically enhances Em-Myc lymphomagenesis. Thus, a new epigenetic regulator of the INK4a/ARF locus can have oncogenic properties in vivo. In addition, we are conducting microarray studies on drug-induced senescence of Em-Myc lymphoma in vivo, and preliminary studies support the role of epigenetic regulation in this process. We are attempting to modulate epigenetic programs through pharmacological means to determine whether such modulation may act alone or in combination with conventional therapy in our model. Thus, utilizing three different approaches we have implicated epigenetic regulation of gene expression in tumor suppression and in response of tumors to drug treatment. Progress on these aims will be discussed. 1. Schmitt C et al Cell 2002 May 3;109(3):335-46. 2. Narita M et al Cell 2003 Jun 13;113(6):703-16
Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder
Authors: D R Gastfriend, J F Rosenbaum
Journal: American Journal of Psychiatry (1989)

Four patients with panic disorder whose panic attacks responded to benzodiazepine treatment but who suffered persistent anxiety improved after addition of buspirone. Despite its lack of antipanic effect, buspirone may offer an adjunctive benefit when added to benzodiazepines in panic disorder.
Vascular Effects of Sirolimus-Eluting Versus Bare-Metal Stents in Diabetic Patients
Authors: Pilar Jiménez-Quevedo, Manel Sabaté, Dominick J. Angiolillo, Marco A. Costa, Fernando Alfonso, Joan Antoni Gómez-Hospital, Rosana Hernández-Antolín, Camino Bañuelos, Javier Goicolea, Francisco Fernández-Avilés, Theodore Bass, Javier Escaned, Raul Moreno, Cristina Fernández, Carlos Macaya
Journal: Journal of the American College of Cardiology (2006)
Higher dose inhaled steroids in childhood asthma
Authors: H. Archer
Journal: BMJ (2001)

Editor—Thomas confirms that intermittent calf compression reduces the rate of pulmonary embolism to 1% after replacement arthroplasty without having the possible side effects of chemoprophylaxis.1 He goes on to state that when the efficacy of foot pumps was compared with that of anticoagulation “the results in terms of preventing deep venous thrombosis were comparable.”

The rest of the editorial is aimed at supporting the use of anticoagulation in these patients. I presume that Thomas is neither an orthopaedic surgeon nor a patient who has had a failed joint replacement; if he was he would not regard an incidence of major bleeding with anticoagulation of 1% as being an “acceptable price to pay.”

His conclusion that anticoagulation is the single most effective way of preventing these complications is not supported by the rest of his editorial. It seems incongruous that he is suggesting using a method of prophylaxis with a 1% rate of major complications to prevent a complication with the same incidence.

If this article is not retracted or a counter-argument published there is a risk that litigation lawyers will use it against the many orthopaedic surgeons who avoid chemoprophylaxis in patients undergoing arthroplasty.
BMS-936564 (Anti-CXCR4 Antibody) Induces Specific Leukemia Cell Mobilization and Objective Clinical Responses In CLL Patients Treated Under a Phase I Clinical Trial
Authors: Manoj Kumar Kashyap, Carlos I. Amaya-Chanaga, Harrison Jones, Eiman A. AlMahasnah, Michael Y. Choi, Michelle R. Kuhne, Lewis Cohen, Peter Sabbatini, Thomas J. Kipps, Pina M. Cardarelli, Januario E. Castro
Journal: Blood (2013)
Abstract 1507: Role of Sarcolemmal ATP-Sensitive K+ Channels in Sinoatrial Node Cells: Evaluation Using Kir6.2 Knockout Mice
Authors: Koichi Fukuzaki, Toshiaki Sato, Masaji Tamagawa, Takashi Miki, Susumu Seino, Haruaki Nakaya
Journal: Circulation (2006)

Cardiac sarcolemmal ATP-sensitive K+ (KATP) channels are composed of two structurally distinct subunits, the inwardly rectifying K+ channel pore subunit Kir6.2 and the sulfonylurea receptor SUR2A. ...
Randomized phase II trial of pegylated liposomal doxorubicin (PLD) with or without anti-platelet-derived growth factor receptor-alpha (PDGFR-alpha) monoclonal antibody IMC-3G3 in platinum-refractory/resistant advanced ovarian cancer.
Authors: W. P. McGuire, G. D. Shah, N. Loizos, H. Youssoufian, E. K. Rowinsky, M. E. Gore
Journal: Journal of Clinical Oncology (2010)

TPS256 Background: Single-agent PLD is an established therapy for platinum-refractory/resistant advanced ovarian cancer with response rates of approximately 20%. This ongoing study will assess antitumor activity and safety of PLD with or without IMC-3G3 in this population. IMC- 3G3 is an IgG1-type recombinant human monoclonal antibody which specifically targets PDGFRα with high affinity, blocks ligand-induced cell mitogenesis and receptor autophosphorylation, and inhibits phosphorylation of the downstream signaling molecules Akt and MAP kinase (Mol Cancer Ther 2005;4:369). PDGFRα is expressed in 52% of ovarian cancers, including in 89% with clear cell histology (Oncogene. 2002;21:6289). PDGF and PDGFRα are often co-expressed in ovarian cancers, suggesting an autocrine mechanism of tumor growth, and PDGFRα expression is associated with shorter survival in patients (Ca Res 1993; 53: 4550). Ovarian cancer-associated ascites fluid contains PDGF, and can stimulate ovarian cancer growth through PDGFRα signaling, highlighting a potential mechanism of intraperitoneal disease spread (Oncogene. 2006;25:2060). IMC-3G3 inhibits proliferation and growth of several human tumor cell lines in vitro and in vivo and enhances the antitumor effect of doxorubicin in xenograft models (ImClone Systems, data on file). Methods: One hundred ten patients with platinum- refractory/resistant ovarian cancer will be enrolled at 13-15 North American and European centers. Progression-free survival is the primary endpoint. Potential associations between clinical outcomes and tumor PDGFRα expression and serum vascular endothelial growth factor (VEGF)/PDGF levels, and the relationship between IMC-3G3 treatment and serum VEGF/PDGF levels will be assessed. Patients will be randomized to receive IMC-3G3 (20 mg/kg) every two weeks with PLD (40 mg/m2) every 4 weeks (Arm A), or doxorubicin alone (Arm B) until disease progression or other withdrawal criteria. Patients in Arm B may receive IMC-3G3 monotherapy upon disease progression. As of January 2010, 25 patients have been enrolled at 6 sites. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ImClone Systems ImClone Systems ImClone Systems